Canaccord raised the firm’s price target on Koru Medical (KRMD) to $6 from $5 and keeps a Buy rating on the shares. The firm updated its model to reflect their new 2027 estimates.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRMD:
- Koru Medical names Eric Schiller CTO
- REPRO-MED Systems Signs New Manufacturing Agreement
- Repro-Med Systems’ Earnings Call Highlights Growth and Challenges
- Koru Medical price target raised to $6.25 from $6 at Craig-Hallum
- Strong Revenue Growth and Strategic Positioning Drive Buy Rating for REPRO-MED Systems